Overview and quick facts
Gilead Sciences is a biopharmaceutical company focused on antiviral drugs and vaccines. It is best known for hepatitis C cures (Sovaldi, Harvoni, Epclusa), HIV prevention (Truvada, Descovy) including PrEP, and emergency response antivirals (Remdesivir). Headquartered in Foster City, California, Gilead operates globally through subsidiaries and has a large pipeline in liver disease, respiratory viruses, and HIV. The following sections explain its history, product portfolio, clinical programs, and access initiatives without speculative commentary.
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Company type | Public biopharmaceutical | SEC filings / corporate website |
| Primary focus | Antivirals and vaccines | Corporate materials |
| Key products (examples) | Sovaldi, Harvoni, Epclusa, Truvada, Descovy, Veklury | Public prescribing information |
| Headquarters | Foster City, California, USA | Corporate SEC disclosures |
History and corporate development
Founded in 1987 by chemist Michael J. Sofia and others, Gilead initially pursued a broad antiviral strategy. It advanced nucleoside analogs and later partnered HCV polymerase inhibitors that became cornerstone drugs. Acquisitions expanded its capabilities and compound library. Over time, Gilead evolved into a company with a large antiviral portfolio and a global commercial infrastructure. Its development path reflects iterative optimization of nucleoside and nucleotide analogs across multiple viral targets.
Timeline of notable milestones
| Date or Period | Event | Why It Matters |
|---|---|---|
| 1987 | Founded | Established focus on antiviral innovation |
| 1990s | Early HCV effort and nucleoside programs | Launched platform chemistry |
| 2011 | Approval of TDF-based regimens | Expanded HIV and HBV options |
| 2013 | Sovaldi (sofosbuvir) launched | Marked curative HCV therapy era |
| 2014 | Harvoni and Epclusa approvals | Broadened curative options |
| 2020 | Veklury (remdesivir) authorization for COVID-19 | Demonstrated pivot to emerging viral threats |
Product portfolio and current assets
Gilead’s portfolio centers on antivirals with differentiated mechanisms and high unmet need. Its offerings include treatments for chronic hepatitis B and C, HIV, and select emerging infections. The company’s late-stage pipeline emphasizes liver disease, latent viruses, and next-generation polymerase and protease inhibitors. Recent additions address resistance patterns and long-acting delivery where clinically appropriate.
Major drug areas
- Hepatitis C: Sovaldi (sofosbuvir), Harvoni (ledipasvir/sofosbuvir), Mavyret (glecapreviter/pibrentasvir), Epclusa (sofosbuvir/velpatasvir)
- HIV: Truvada (emtricitabine/tenofovir disoproxil fumarate) and Descovy (emtricitabine/tenofovir alafenamide) for treatment and PrEP; Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide)
- Emerging viruses: Veklury (remdesivir) for COVID-19
- Research areas: HBV cure strategies, broad-spectrum antivirals, long-acting PrEP
Research pipeline and development focus
Public disclosures and conference abstracts indicate ongoing programs in hepatitis B functional cure, broadly neutralizing antibodies, and next-generation nucleoside/nucleotide analogs. The pipeline includes small-molecule inhibitors, capsid assembly modulators, and immunomodulators. While some candidates advance to later stages, others remain earlier. Gilead also explores fixed-dose combinations to improve adherence and outcomes in people living with HIV and HCV.
Pipeline themes
- HBV cure strategies including entry inhibitors and therapeutic vaccines
- Pan-viral polymerase and protease inhibitors
- Long-acting injectable PrEP and multimodal delivery
- Resistance-aware combinations for difficult-to-treat variants
Global access and patient support
Gilead operates patient assistance programs, voluntary licensing, and tiered pricing in low- and middle-income countries. These initiatives aim to expand access to curative HCV therapies and PrEP while addressing affordability. Collaboration with generic manufacturers and local health systems is emphasized to broaden coverage. Programs are periodically updated in response to policy changes and clinical guidelines.
Access initiatives overview
- Gilead Advancing Access: expanded eligibility for investigational and approved therapies
- Copay Assistance and foundation co-pay support in the United States
- Voluntary licenses and tiered pricing for low-income countries
- Partnerships with NGOs to strengthen testing and linkage to care
Leadership and governance
The executive team and board oversee a science-driven approach to antiviral development and commercialization. Governance includes committees on science, safety, and access. Public filings describe roles, terms, and oversight structures. Decision-making emphasizes clinical evidence, regulatory strategy, and operational execution across regions.
Considerations for stakeholders
For clinicians, Gilead options are appropriate when guideline-endorsed regimens match patient characteristics and resistance profiles. For patients, access pathways and support services can reduce out-of-pocket costs. For investors, the company’s pipeline and licensing activity are relevant inputs alongside broader market and regulatory factors. Ongoing updates from regulatory authorities and advisory bodies may affect product use and payer positioning.